Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report
OncoReview · 2020
DOI: 10.24292/01.or.120260320 ↗Kurz gefasst
Fallbericht in der Zeitschrift OncoReview, 2020. Verfasst von Piotr Skalij und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
A case of 73-year-old patient with metastatic colorectal cancer who underwent trifluridine/tipiracil therapy within the VI line was presented. Treatment with trifluridine/tipiracil allowed to achieve stabilization of the existing cancer for nearly 7 months.
Zitieren
APA
Skalij, P., Tokajuk, P., Jelski, S., & Wojtukiewicz, M. (2020). Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report. OncoReview. https://doi.org/10.24292/01.or.120260320
Vancouver
Skalij P, Tokajuk P, Jelski S, Wojtukiewicz M. Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report. OncoReview. 2020. doi:10.24292/01.or.120260320
BibTeX
@article{Skalij2020,
author = {Skalij, Piotr and Tokajuk, Piotr and Jelski, Stefan and Wojtukiewicz, Marek},
title = {Long-term disease control during TAS-102 therapy in the VI line treatment in a 73-year-old mCRC patient. A case report},
journal = {OncoReview},
year = {2020},
doi = {10.24292/01.or.120260320}
}
EUVIMED